NCT04999293

Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention

Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,505 (actual)
• Sponsor: The First Affiliated Hospital of Dalian Medical University · Academic / Other
• Sex: All
• Age: 75 Years
• Healthy volunteers: Not accepted

Summary

The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.

Conditions

• Platelet Aggregation Inhibitors
• Dual Anti-Platelet Therapy
• Aged
• Percutaneous Coronary Intervention

Interventions

Type	Name	Description
DRUG	Ticagrelor	Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.

Timeline

• Start date: 2021-07-20
• Primary completion: 2021-08-05
• Completion: 2021-08-06
• First posted: 2021-08-10
• Last updated: 2021-08-10

Locations

1 site across 1 country: China